Develops investigational therapies for neurological disorders, including TA-ERT for patients with MPS IIIB.
10-K for FY2025, filed Mar 9, 2026
Patients with MPS IIIB are treated by a small set of specialists. Spruce plans to market TA-ERT through its own U.S. commercial team and use regional collaborators and distributors in other markets.
10-K for FY2025, filed Mar 9, 2026Seek regulatory approval and maximize the U.S. commercial potential of TA-ERT for the treatment of MPS IIIB. We intend to seek U.S.…View ↗
Commercialize globally through a patient-focused organization. We seek to commercialize TA-ERT and its other investigational products…View ↗
We are in the process of scaling up a commercial organization for the marketing, sales, and distribution of pharmaceutical products. We are…View ↗
10-Q for Q3 FY2026, filed Nov 9, 2026
−$24MView ↗
8-K, filed Nov 9, 2026
“We have also taken deliberate steps to strengthen our balance sheet and sharpen our strategic focus,” continued Dr. Szwarcberg. “Our…View ↗
8-K, filed Mar 20, 2026
On March 16, 2026, Spruce Biosciences, Inc. (the “Company”) entered into a Termination Agreement (the “Termination Agreement”) with Kaken…View ↗
From endocrine to neurological focus
The older report centered on tildacerfont for rare endocrine disorders, especially classic CAH; the latest centers on TA-ERT for MPS IIIB, while also listing a preclinical CAH program.
10-K for FY2022, filed Mar 16, 2023We are a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with…View ↗
Loading...